from research to diagnosis and therapy

Final Program
Annual Congress SSAI-SGAI
Advances in immunology and allergology:
from research to diagnosis and therapy
March 17–18, 2011, Lugano, Ticino
www.ctlag-congress.ch
Advancing the
Science of Cytometry
It’s about
Capturing the Event
Gallios is engineered to meet
the challenges of an increasingly
complex analytical environment.
Built on a platform designed for
reliability and stability, the Gallios
offers superior resolution and
cell/particle characterization
without sacrificing analytical
speed or data integrity.
Higher Electronic Sampling Rate = Improves Characterization
The Gallios:
Current Technology
BCI Gallios
• Samples information at 40MHz display data
on a 1,048,576 channel scale.
• Collects 4 times the information compared
to a typical data display of 10MHz.
Based on 2 sec cycle time representing
Based on 0.5 sec cycle time representing
10MHZ DSP
40MHZ DSP
• Displays information with 4 times
the resolution of a standard 262,144
channel display.
Whether your challenges are dim markers,
rare events or just routine analysis—Gallios
is the cytometer to capture your events.
Find out more at
www.GalliosRevealed.com
ForResearchUseOnly.Notfordiagnosticprocedures.
GalliosisatrademarkofBeckmanCoulter,Inc.
BeckmanCoulterandthestylizedlogoareregisteredtrademarksofBeckmanCoulter,Inc.
B2010-11707P-14399A
www.coulterflow.com
Contents
Welcome to Lugano
5
Organization
9
Program overview – Thursday, March 17, 2011
11
Program – Thursday, March 17, 2011
13
Program overview – Friday, March 18, 2011
21
Program – Friday, March 18, 2011
24
Chairpersons and speakers
32
General Information
34
Sponsors
38
Exhibitors
39
Map of Lugano
40
Opera on the cover: «Ticino», by Daniele Buzzi, 1946
taken from: Roberto Cavalli, «100 years of Ticino posters (1890–1990)», part 1, Germignana (VA),
Art Editions Jansonius, 2008, page 46
3
Add life, add XOLAIR®
Mehr LEBENSQUALITÄT bei allergischem
Asthma dank Anti-IgE-Therapie!1
Kassenzulässig*
Referenzen:
1. Humbert M, Beasley R, Ayres J, et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy, 2005
Mar;60(3):309-16. *Kassenzulässig mit folgender Limitierung: "Schweres, gegenüber anderen Therapien resistentes, allergisches Asthma unter der Voraussetzung, dass die Behandlung durch einen Spezialarzt (Pneumologen, Allergologen) erfolgt.
Die Weiterbehandlung des Patienten durch einen Grundversorger bedarf der Bewilligung des Vertrauensarztes der Krankenkasse." (gemäss Verfügung BAG vom 16.11.2006).
I520, August 2009
Kurzfachinformation
XOLAIR® (Omalizumab). Z: Omalizumab; Stechampulle mit Pulver 150 mg Omalizumab und Lösungsmittel zur Herstellung einer Injektionslösung. I: In Kombination mit anderen Asthmatherapien zur verbesserten Asthmakontrolle bei Erwachsenen
und Jugendlichen (ab 12 Jahren) mit schwerem persistierendem allergischem Asthma (positiver Hauttest oder in vitro-Reaktivität gegen ein ganzjährig auftretendes Aeroallergen), falls diese trotz täglicher Therapie mit hoch dosierten inhalativen
Kortikosteroiden und einem langwirksamen Beta2-Agonisten eine reduzierte Lungenfunktion (FEV1 < 80 %) haben als auch unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und Asthma-Exazerbationen hatten. D:
Erwachsene und Kinder ab 12 Jahren: 75 - 375 mg XOLAIR® 1 - 2 x/Monat basierend auf dem IgE-Basis-Wert (I.E./ml) im Serum und des Körpergewichts des Patienten. Einzelheiten s. Arzneimittel-Kompendium der Schweiz®. KI: Überempfindlichkeit
gegenüber dem Wirkstoff oder einem der Inhaltsstoffe. VM: Nicht indiziert zur Behandlung von akuten Asthma-Exazerbationen, akuten Bronchospasmen und Status asthmaticus. Nicht untersucht bei Hyper-Immunglobulin-E-Syndrom, allergischer
bronchopulmonaler Aspergillose, Prävention allergischer Reaktionen, atopischer Dermatitis, allergischer Rhinitis, Lebensmittelallergien, Autoimmunerkrankungen, Immunkomplex-vermittelten Zuständen, bestehender Nieren- oder
Leberfunktionsstörung. Reduktion von Kortikosteroiden unter ärztlicher Aufsicht. Enthält Saccharose: Patienten mit Diabetes mellitus, Glukose-GalaktoseMalabsorption, Fruktose-Intoleranz, Saccharose-Isomaltase-Mangel müssen darauf hingewiesen werden. Allergische Reaktionen oder lebensbedrohliche
Anaphylaxie und anaphylaktischer Schock können auftreten; Probleme im Zusammenhang mit Immunogenität, parasitären (Wurm-) Infektionen oder
Malignitäten können auftreten. Einzelheiten s. Arzneimittel-Kompendium der Schweiz®. IA: Es gibt keine Hinweise auf veränderte Sicherheit durch andere i.a. eingesetzten Asthmamedikamente. Die Wirksamkeit der Behandlung in Kombination mit spezifischer Immuntherapie wurde nicht nachgewiesen.
UW: Häufig: Kopfschmerzen, Reaktionen an der Injektionsstelle wie Schmerzen, Erythem, Pruritus, Schwellung. Gelegentlich: Schwindel,
Schläfrigkeit, Parästhesie, Synkope, orthostatische Hypotonie, Flush, Pharyngitis, Husten, allergische Bronchospasmen, Nausea, Diarrhoe,
Dyspepsie, Urtikaria, Rash, Pruritus, Photosensibilität, Gewichtszunahme, Müdigkeit, Anschwellen der Arme, grippeähnliche Symptome. Selten
und sehr selten s. Arzneimittel-Kompendium der Schweiz®. Postmarketing: Anaphylaxie und anaphylaktoide Reaktionen, Alopezie, idiopathische
schwere Thrombozytopenie, allergische granulomatöse Angiitis (d.h. Churg-Strauss-Syndrom), Arthralgie, Myalgie, Gelenkschwellung.
Malignitäten, Thrombozyten, Labordaten, Parasitäre Infektionen: s. Arzneimittel-Kompendium der Schweiz®. P: 1 Stechampulle zu 150 mg mit
1 Lösungsmittelampulle zu 2 ml: je 1*. Verkaufskategorie: (B). *kassenzulässig. Verkaufskategorie: B. Weitere Informationen entnehmen Sie
bitte dem Arzneimittel-Kompendium der Schweiz®. ZUL: Novartis Pharma Schweiz AG, Postfach, 3001 Bern. www.novartispharma.ch V2
Novartis Pharma Schweiz AG, Postfach, 3001 Bern. www.novartispharma.ch
Welcome to Lugano
Dear members
of the Swiss Society of Allergology and Immunology,
dear friends,
colleagues and guests,
I am very happy inviting you to the annual meeting of our society, which
will take place in the hopefully sunny Ticino. The organizers around
Federica ­Sallusto and Brunello Wüthrich have done a tremendous job and
have found a perfect balance between the interests and needs of the
basic researchers, the laboratory immunologists as well as the practicing
allergo­logists.
It is now up to you to fill the congress with life by showing your interest
and participation in the different lectures. I am looking forward to seeing
you all in Lugano and wish you a successful meeting.
Sincerely,
Prof. Dr. med. A. Bircher
President SSAI
5
Welcome to Lugano
Dear friends and colleagues,
It is with a great pleasure that we welcome you to the Annual Congress
of the Swiss Society for Allergology and Immunology (SGAI-SSAI).
The Congress is organized by the Institute for Research in Biomedicine
(IRB) together with the Society of Allergologists and Immunologists of
Ticino (STAI) and will feature joint Symposia with the European Academy
of Dermatology and Venereology (EADV) and the Swiss Multiple Sclerosis (MS) Society.
The meeting in Lugano brings together established basic scientists and
clinicians along with young researchers and residents, postdocs and
students who will present their work at symposia, workshops and poster
sessions. It is our policy, and the policy of SGAI, to support the new
generations of immunologists and allergologists and to promote an inter­
active environment that enriches both senior and junior investigators.
The Congress Opening Lecture will be given by John O’Shea who will
discuss the «Transcriptional and epigenetic control of T cell differentiation».
Thomas Schwartz will give the SGAI-EADV Joint Lecture with the title
«Dermatoimmunology: dogmas going through a radical change», David
Hafler will give the SGAI-MS Society Joint Lecture «The genetics of
multiple sclerosis», and Jean-Claude Weill will give a Plenary Lecture on «Multiple layers of B cell memory». The program features 12 Symposia,
6 Sessions for short talks, the SGAI Professional Political Forum and
Corporate Lunch Symposia. The SGAI-SSAI General assembly will be held
on Thursday at 17.30. All members of the society are welcome to attend
and contribute to the assembly.
As complement to the scientific program, all participants are invited to
the reception on Thursday, which is kindly offered by the City of Lugano,
and to participate to the Gala dinner at the «La Perla Wine and Dine»
Restaurant on Casinò di Lugano’s top floor, which boasts an incomparable
view of the lake and the gulf of Lugano. We hope you will also have the
opportunity to enjoy the beauty of the Canton Ticino that offers spectacular
natural surroundings at the foot of the Alps and in the midst of the Lake
district.
6
In this occasion we would like to express our gratitude to the members
of the Organizing Committee for helping us raise funds and selecting
abstracts for oral and poster presentation. We would like also to express
our appreciation to the public and corporate sponsors. Without their
support and commitment the congress would not have been possible.
We are finally grateful to invited speakers and chairpersons and to the
participants for their contribution to the meeting.
We wish you all a pleasant stay.
On behalf of the Organizing Committee
Presidents of the Organizing Committee
Federica Sallusto
Brunello Wüthrich
7
Neu!
Für mehr Genuss
Reduziert Histamin an der Quelle
Das Enzym Diaminooxidase in
kann den Histamingehalt im
Speisebrei vermindern
Xanapharm AG | Terrassenweg 1a | CH-6301 Zug
www.xanapharm.com | info@xanapharm.com
Organization
Presidents of the Organizing Committee
Federica Sallusto, IRB, Bellinzona
(E-mail: federica.sallusto@irb.unisi.ch)
Brunello Wüthrich, STAI, Zollikerberg
(E-mail: bs.wuethrich@bluewin.ch)
President of the Swiss Society for Allergology and Immunology
Andreas Bircher, Department of Dermatology,
University Hospital Basel
Members of the local Organizing and Scientific Committee
Silvy Bach-Bizzozero, STAI, Bellinzona
Massimiliano Fontana, STAI, Mendrisio
Stefano Gilardi, EADV, Locarno
Fabio Grassi, IRB, Bellinzona
Franco Keller, STAI, Bellinzona
Jean Pierre Lantin, STAI, Lugano-Pregassona
Antonio Lanzavecchia, IRB, Bellinzona
Silvia Monticelli, IRB, Bellinzona
Myriam Schluep, Swiss MS Society
Rocco Torricelli, STAI, Lugano-Paradiso
Mariagrazia Uguccioni, IRB, Bellinzona
Gianluca Vanini, STAI, Lugano
Administrative Congress Organization
Convention Team Lucerne AG, Oberseeburg 10, 6006 Lucerne
Tel. +41 41 371 18 60, Fax +41 41 371 18 61 (before congress)
Tel. +41 58 866 66 78, Natel 079 699 94 79 (during congress)
E-mail: ctlag@bluewin.ch
www.ctlag-congress.ch
9
Effektive Asthmakontrolle
zu jeder Jahreszeit
Effektive Asthmakontrolle
bei Asthmapatienten mit
allergischer Rhinitis.
1–4
Grössere Wirksamkeit
als Add-On-Therapie zu ICS als
die Verdopplung der ICS-Dosis
bei komorbiden Patienten
(COMPACT-Post-hoc-Analyse).
5
GINA- und ARIA-Leitlinien
empfehlen LTRAs zur Behandlung
der oberen und unteren Atemwege.
6,7
Zur Behandlung von Asthma und
allergischer Rhinitis bei Asthmapatienten,
bei denen SINGULAIR indiziert ist.
®
Referenzen:
1. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204 – 211.
2. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year double blind, randomised,
comparative trial. BMJ 2003;327:891 – 896.
3. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549 – 1558.
4. Busse WW, Casale TB, Dykewicz MS, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006;96:60 – 68.
5. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT Trial. Allergy 2006;61:737 – 742.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2009. www.ginasthma.com/download.asp?intId=345. Aufgerufen am 12.01.2010.
7. Allergic Rhinitis and its Impact on Asthma (ARIA). Management of Allergic Rhinitis and Its Impact on Asthma: Pocket Guide. www.whiar.org/docs/ARIA_WR_08_View_WM.pdf. Aufgerufen am 08.02.2010.
Konsultieren Sie bitte vor der Verschreibung von SINGULAIR die komplette Fachinformation im Arzneimittel-Kompendium der Schweiz.
®
Abgekürzte Fachinformation SINGULAIR : Indikation: Chronisches Bronchialasthma bei Erwachsenen und Kindern ab 6 Jahren. Bei Kindern von 2 bis 5 Jahren mit gesicherter Asthmadiagnose: a) als Monotherapie bei leichten,
nicht steroidpflichtigen Formen; b) als Zusatztherapie zu Kortikoiden bei schwereren Formen. Bei Kindern von 6 Monaten bis 2 Jahren mit gesicherter Asthmadiagnose: a) als Monotherapie bei leichten, nicht steroidpflichtigen Formen,
vor allem wenn eine Inhalationstherapie schwierig durchführbar ist; b) als Zusatztherapie zu Kortikoiden bei schweren Formen. Linderung von Symptomen der saisonalen und perennialen allergischen Rhinitis bei Erwachsenen und
Kindern ab 2 Jahren. Dosierung/Anwendung: Erwachsene eine 10 mg Tablette pro Tag. 6 – 14 jährige Kinder eine 5 mg Kautablette pro Tag. 2 – 5 jährige Kinder eine 4 mg Kautablette oder ein Sachet 4 mg pro Tag. 6 monatige –
2 jährige Kinder ein Sachet 4 mg pro Tag. Für die Behandlung von Asthma sollte die Dosis am Abend vor der Bettruhe, für die Behandlung der allergischen Rhinitis sollte sie entweder morgens oder abends eingenommen werden.
SINGULAIR kann mit oder ohne gleichzeitige Nahrung eingenommen werden. SINGULAIR orales Granulat kann entweder direkt auf die Zunge oder in den Mund gegeben werden oder vermischt auf einem Löffel mit weicher
Nahrung oder eingerührt in einem Teelöffel Babynahrung oder Muttermilch (jedoch nicht in andere Flüssigkeiten) und sollte innerhalb 15 Minuten nach Öffnen des Sachets verabreicht werden. SINGULAIR kann zu einer bestehenden
Asthmatherapie mit inhalativen Kortikoiden oder ß2-Agonisten nach Bedarf hinzugefügt werden. SINGULAIR bringt zusätzlichen klinischen Nutzen für Patienten unter inhalativen Kortikoiden. Kontraindikationen: Überempfindlichkeit gegenüber einem der Bestandteile dieses Produkts. Vorsichtsmassnahmen: SINGULAIR sollte nicht zur Behandlung von akuten Asthmaanfällen eingesetzt werden. Obwohl die Dosis von gleichzeitigen inhalativen Kortikoiden
unter ärztlicher Aufsicht stufenweise reduziert werden kann, sollte SINGULAIR nicht als plötzlicher Ersatz für inhalative oder orale Kortikoide eingenommen werden. Die Reduktion der systemischen Kortikosteroid-Dosis führte bei
Patienten unter Leukotrien-Rezeptor-Antagonisten in seltenen Fällen zu einer systemischen eosinophilen Vaskulitis. Unerwünschte Wirkungen: Gesamtinzidenz von unter SINGULAIR aufgetretenen Nebenwirkungen war mit Plazebo vergleichbar. Erwachsene: Dyspepsie, Bauchschmerzen, Zahnschmerzen und Kopfschmerzen mit höherer Inzidenz als unter Placebo. Inzidenzrate dieser Erscheinungen in beiden Gruppen ist nicht signifikant unterschiedlich.
Kinder: Kopfschmerzen (Kinder 6 – 14 J.) und Durst (Kinder 2 – 5 J.) mit einer höheren Inzidenz als unter Placebo, Durchfall, Hyperkinesie, Asthma, ekzematöse Dermatitis und Hautausschlag (Kinder 6 Mt. – 2 J.) mit tendentiell höherer
Inzidenz als unter Placebo. Inzidenzrate dieser Erscheinungen in beiden Gruppen nicht signifikant unterschiedlich. Interaktionen: SINGULAIR kann gleichzeitig mit anderen Substanzen, die routinemässig zur chronischen Asthmabehandlung und Behandlung der allergischen Rhinitis verwendet werden, verabreicht werden. Keine wesentliche Wirkung auf die Pharmakokinetik von: Prednisolon, orale Antikonzeptiva, Terfenadin, Digoxin und Warfarin. In in vitro
Studien ist Montelukast ein Inhibitor von CYP2C8, es wurden jedoch keine in vivo Studien durchgeführt. Packungen: SINGULAIR (Montelukast): Filmtabletten zu 10 mg: 28 und 98, Kautabletten zu 5 mg: 28 und 98, Kautabletten zu
4 mg: 28 und 98, Sachets zu 4 mg oralem Granulat: 28. Verkaufskategorie B. Stand der Information: Februar 2009. Kassenpflichtig.
® Eingetragenes Markenzeichen von Merck Sharp & Dohme Corp., eine Tochtergesellschaft von Merck & Co., Inc., Whitehouse Station, NJ, U.S.A.
02-2011-SGA-2010-CH-1751 J
®
®
®
®
®
®
®
®
®
®
MERCK SHARP & DOHME-CHIBRET AG
Schaffhauserstrasse 136, CH-8152 Opfikon-Glattbrugg
Tel. +41 44 828 71 11, Fax +41 44 828 72 10, www.msd.ch
Program overview
Thursday, March 17, 2011
Room A
Room B1
Room B3
Room C
(629 persons sem.)
(144 persons sem.)
(120 persons sem.)
(100 persons theat.)
10.00–11.20 Registration and Welcome Coffee / Poster viewing / Commercial exhibition
11.20–12.10 Symposium 1
Symposium 2
Clinical Immunology
Basic Immunology
Ed Palmer (CH)
George Holländer (CH)
Margot Thome-Miazza (CH) Onur Boyman (CH)
Symposium 3
Allergology
Bernhard Clot (CH)
Claudio Ortolani (I)
12.15–13.00 Opening lecture 1 (Room A)
John O’Shea (USA)
13.00–14.30 Lunch break / Poster viewing / Commercial exhibition
13.15–14.15
Lunch Symposium 1
Merck Serono SA
SSAI-SGAI
Laboratory
Diagnostics Meeting
14.30–16.00 Symposium 4
Symposium 6
Allergo-Immuno-
Dermatology
Symposium 5
Laboratory
Diagnostics
Werner Aberer (A)
Andreas Bircher (CH)
Lars French (CH)
Alison Levoguer (UK)
Angela Vincent (UK)
Steven Stapel (NL)
Basic Immunology
Marco Colonna (USA)
Olivier Lantz (F)
Gennaro De Libero (CH)
Short Presentation
SSAI-SGAI
Professional
political forum
16.00–16.30 Lunch break / Poster viewing / Commercial exhibition
16.30–17.30 Short Communi-
cations: Basic
Immunology 1
Short Communi-
cations: Clinical
Immunology
Short Communications: Laboratory
Diagnostics
17.30–19.00 General Assembly SSAI-SGAI (Room B1)
17.30–19.30 Reception at the Convention Center
20.00–23.00 Gala Dinner at the restaurant «La Perla» at the Casino of Lugano
11
MerckSeronoisa
divisionofMerck
SGAI/SSAI Lugano, Switzerland
B Cell therapies in auto immune diseases
Thursday, March 17th 2011, 13.15 pm - 14.15 pm
Chair:ProfessorDavidIsenberg
13.15 - 13.45 pm
CatherineBarbey,PhD,MerckSeronoSAGeneva
BLySandAPRILinhibitioninrheumaticautoimmunediseases
13.45 - 14.15 pm
ProfessorDavidIsenberg,UCLCenterofRheumatology
Celldepletioninautoimmunerheumaticdiseases
Program
Thursday, March 17, 2011
10.00–11.20 Registration
Welcome Coffee (supported by Zeller Medical)
Poster Exhibition, Industry Exhibition
11.20–12.10 Symposium 1: Basic Immunology
Room A
Chair:Fabio Grassi (Bellinzona, CH), Antonius G. Rolink (Basel, CH)
Ed Palmer (Basel, CH)
Thymic selection and T cell tolerance
Margot Thome-Miazza (Lausanne, CH)
Signaling pathways for lymphocyte activation and survival
Symposium 2: Clinical Immunology
Room B1
Chair:Christian Münz (Zurich, CH), François Spertini (Lausanne, CH)
George Holländer (Basel, CH)
The role of the thymus in allogeneic hematopoietic stem cell
­trans­plantation
Onur Boyman (Zurich, CH)
Cytokines in immunotherapy
Symposium 3: Allergology: Influence of Climate and
Environmental Changes in Allergic Sensitization
(supported by Swiss Association of Aerobiology)
Room B3
Chair: Brunello Wüthrich (Zurich, CH), Massimiliano Fontana (Mendrisio, CH)
Bernard Clot (Payerne, CH)
Interregional variations of pollen, climate change and future trends
in ­Switzerland
Claudio Ortolani (Milano, I)
Influence of environmental changes on food allergy
12.15–13.00 Opening lecture 1
Room A
Chair:Federica Sallusto (Bellinzona, CH), Andreas Bircher (Basel, CH)
John O’Shea (Bethesda, USA)
Transcriptional and epigenetic control of helper T cell differentiation
13.00–14.30 Lunch break in Exhibit Hall and poster viewing
13
13.15–14.15 SSAI-SGAI Professional Political Forum
13.15–14.15SSAI-SGAI Laboratory Diagnostics Meeting
ANA and ANCA testing in Switzerland
Ingmar Heijnen (Basel, CH)
ANA, anti-dsDNA, and anti-ENA testing in Switzerland:
Results of a laboratory survey
Pascale Roux-Lombard (Geneva, CH)
Autoimmunity external quality assessment (UK-NEQAS):
First results
13.15–14.15 Lunch Symposium 1
B Cell Therapies in Auto Immune Diseases
(Organized and sponsored by Merck Serono SA)
Room C
Room B3
Room B1
14.30–16.00 Symposium 4: Basic Immunology
Room A
Chair:Annette Oxenius (Zurich, CH), Hans Acha-Orbea (Lausanne, CH)
Marco Colonna (St. Louis, USA)
NK cells in innate and adaptive immunity
Olivier Lantz (Paris, F)
Development and function of mucosal-associated invariant T cells
Gennaro De Libero (Basel, CH)
The cellular and biochemical rules of lipid antigen presentation
Short presentation:
Alena Donda (Epalinges, CH)
Sustained iNKT cell activation by CD1d fusion proteins leads to
­efficient tumor inhibition and is optimized when combined with
MDSC inactivation
Symposium 5: Laboratory Diagnostics
(supported by Sodiag SA)
Room B3
Chair:Franco Keller (Bellinzona, CH), Stephan Regenass (Zurich, CH)
Alison Levoguer (Birmingham, UK)
Serum free light chains and monoclonal gammopathies: recent changes
Angela Vincent (Oxford, UK)
Autoantibodies in neurological syndromes
Steven Stapel (Amsterdam, NL)
Antibody formation toward drugs and their consequence
14
Symposium 6: Allergo-Immuno-Dermatology
Room B1
New Aspects of Contact Allergy and of Autoinflammatory Skin Disease
Chair:Alberto Giannetti (Modena, I), Stefano Gilardi (Locarno, CH)
Werner Aberer (Graz, A)
Fragrance allergy: new aspects
Andreas Bircher (Basel, CH)
Sensitization to alloy metals used in orthopedic surgery and dentistry
Lars French (Zurich, CH)
Autoinflammatory skin diseases
16.00–16.30 Coffee break in Exhibit Hall and poster viewing
16.30–17.30 Short Communications: Basic Immunology 1
Room A
Chair: Burkhard Ludewig (St. Gallen, CH), Nicola Harris (Lausanne, CH)
BI1-S1 Context specific affinity thresholds for CD8 T cell
activation
D. Zehn1, L. Hanna-El-Daher1, L. Carrie1, M. Bevan2
Swiss Vaccine Research Institute/CHUV – Division of Immunology
and Allergy, Lausanne
2 Department of Immunology, Howard Hughes Medical Institute,
University of Washington, Seattle, USA
1 BI1-S2 Contribution of individual T cell specificities to the
resolution of chronic viral infection
S. Johnson1, A. Bergthaler1, L. Flatz1, D. Pinschewer1
1 Department of Pathology and Immunology and W.H.O.
collaborating Centre for Neonatal Vaccinology, University of Geneva,
Geneva
BI1-S3
The role of non-hematopoietic MHC class II expression
in immune responses and tolerance
C. Thelemann1, M. Coutaz1, S. Hugues2, M. Rosa1, B. Weber3,
N. Dickgreber3, W. Reith2, C. Müller3, H. Acha-Orbea1
1 Department of Biochemistry, University of Lausanne, Lausanne
2 Department of Pathology and Immunology, University of Geneva,
Geneva
3 Institute of Pathology, University of Berne, Berne
15
BI1-S4
Unexpected role for lymph node stromal cells
in suppressing T cell proliferation
S. Luther1, L. Scarpellino1, S. Flavell2, A. Tomei3, M. Swartz3,
P. Nelson4, M. Heikenwälder5, H. Acha-Orbea1, C. Buckley2,
S. Siegert1
1 Dep. of Biochemistry, University of Lausanne, Epalinges
2 MRC Center Birmingham, Birmingham, UK
3 EPF Lausanne, Lausanne
4 LMU Munich, Munich
5 TU Munich, Munich
BI1-S5
On the role of IL-1beta and CNS myeloid cells in
EAE pathogenesis
F. Ronchi1, A. Reboldi2, A. Lanzavecchia1, F. Sallusto1
1 Institute for Research in Biomedicine, Bellinzona
2 University of California, San Francisco, USA
Short Communications: Laboratory Diagnostics
Chair: E. Dayer (Sion, CH), W. Fierz (Schaan, CH)
Room B3
LD-S1
Enumeration of lymphocyte subpopulations: from a 3-color
multiple tubes to a six-color single-tube technique
L. Bernasconi1, D. Engler1, P. Fernandez1, A. Huber1
1 Kantonsspital Aarau, Aarau
LD-S2
Detection and clinical significance of coexisisting
antitopoisomerase I and anticentromere antibodies
in patients with systemic sclerosis: a EUSTAR
group-based study
I. Heijnen1, B. Bannert2, C. Tyndall2, UA. Walker2
1 Medical Immunology, Laboratory Medicine, University Hospital
Basel, Basel
2 Basel University Dept. of Rheumatology, Felix Platter-Spital,
Basel
16
LD-S3
Standardization of Autoantibody Detection Using Indirect
Immuno­fluorescence on HEp-2 Cells
P. von Landenberg1
1 Institut für Labormedizin, Olten/Solothurn
LD-S4
A vexing case of severe pruritus and elevated serum
tryptase after systemic antifungal treatment resolving
as primary billiary cirrhosis / autoimmune hepatitis
C. Murer1, E. Sailer2, S. Regenass3, U. Mueller4, L. French2,
P. Schmid-Grendelmeier1
1 Allergy Unit, Dept. of Dermatology, University Hospital, Zurich
2 Dept. of Dermatology, University Hospital, Zurich
3 Institute for Clinical Immunology, Zurich
4 Allergy Unit Zieglerspital, Berne
LD S5
The Swiss National Registry of Primary Immunodeficiency
Diseases (PID)
M. M. Hoernes1, B. Drexel1, J. Reichenbach1, R. A. Seger1
1 Div. Immunology, Haematology, BMT, University Children’s
Hospital Zurich, Zurich
Short Communications: Clinical Immunology
Chair: Daniel Speiser (Lausanne, CH)
CI-S1
Room B1
Heterozygous STAT3 mutations in 5 Swiss patients of
4 unrelated families with classic autosomal dominant
Hyper IgE syndrome
J. Reichenbach1, L. F. Schimke2, M. Hoernes1, B. Drexel1,
S. Rylaarsdam3, H. Ochs3, J. Sawalle-Belohradsky2, R. A. Seger1,
E. D. Renner2
1 Division of Immunology/Hematology/BMT, University Children’s
Hospital Zurich, Zurich
2 Dr. von Haunersches Kinderspital, Ludwig Maximilians
University, Munich, Munich
3 Department of Pediatrics, University of Washington School of
Medicine and Children’s Hospital, Seattle, USA
17
CI-S2
Single cell gene expression profiling reveals
qualitatively distinct CD8 T cells elicited by different
gene-based vaccines
L. Flatz1, R. Roychoudhuri2, M. Honda2, A. Filali3, JP. Goulet3,
N. Kettaf3, M. Roederer2, E. Haddad3, R. P. Sékaly3, G. J. Nabel2
1 Institute of Dermatology, CHUV, Lausanne
2 Vaccine Research Center, NIAID, NIH, Bethesda MD
3 Vaccine and Gene Therapy Institute, Port St. Lucie FL
CI-S3
Enhanced IL-17A and IL-22 production by peripheral
blood mononuclear cells distinguish systemic sclerosis
from healthy individuals
N. C. Brembilla1, M.E. Truchetet1, E. Montanari1, Y. Allanore2,
C. Chizzolini1
1 Immunology & Allergy, University Hospital and School of
Medicine, Geneva
2 Rheumatology, Cochin Hospital, Paris, France
CI-S4
18
Telomeric rather than centromeric activating KIR genes
protect from reactivation of cytomegalovirus infection after
kidney trans­plantation
J. Villard1, M. Stern2, K. Hadaya3, G. Hönger4, P. Y. Martin3,
C. Hess4
1 Transplantation Immunology Unit, Division of Immunology
and Allergy, Department of Medicine and Laboratory Medicine,
Geneva University Hospital and Medical School, Geneva
2 Division of Hematology, University Hospital Basel, Basel
3 Service of Nephrology and Transplantation
4 Immunobiology Laboratory, Department of Biomedicine,
University Hospital Basel, Basel
CI-S5
De novo anti-HLA antibody after pandemic H1N1 and
seasonal influenza immunization in kidney transplant
recipients
J. Villard1, I. Katarinis2, K. Hadaya2, R. Duquesnoy3,
S. Ferrari-Lacraz1, S. Meier4, C. van Delden4, P. Y. Martin2,
C. A. Siegrist4
1 Transplantation Immunology Unit, Departments of Medicine and
Laboratory Medicine, University Hospital of Geneva, Geneva
2 Service of Nephrology, Department of Medicine, University Hospital
of Geneva, Geneva
3 Department of Pathology, University of Pittsburgh Medical Center,
Pittsburgh
4 Center of Vaccinology, Department of Pediatrics, University
Hospital of Geneva, Geneva
17.30–19.00 General Assembly SSAI-SGAI
Room B1
17.30–19.30 Reception at the Convention Center offered by the City of Lugano
20.00–23.00 Gala Dinner at the restaurant «La Perla»,
at the Casino of Lugano
19
1
#
un
Starke Wirkung.1
Kassenzulässig Opatanol® 1mg/ml Augentropfen
Zusammensetzung: Olopatadinum 1mg/ml, Conserv.: Benzalkonii chloridum. Indikationen: Zur Behandlung von okulären Symptomen der saisonalen allergischen Konjunktivitis bei Erwachsenen
und Kindern ab 3 Jahren. Dosierung/Anwendung: Einen Tropfen Opatanol® zweimal täglich in den Bindehautsack des (der) betroffene(n) Auge(n) eintropfen (im Abstand von 8 Stunden). Die
Behandlung kann falls notwendig bis zu 4 Monate fortgesetzt werden. Kontraindikationen: Überempfindlichkeit gegenüber Olopatadin oder einem der Hilfsstoffe. Vorsichtsmassnahmen: Opatanol®
wird, obwohl topisch angewendet, auch systemisch resorbiert. Bei Anzeichen schwerwiegender Symptome oder bei Überempfindlichkeitreaktionen ist die Behandlung mit diesem Präparat
abzubrechen. Interaktionen: Es wurden am Menschen keine klinischen Studien mit Opatanol® zu Wechselwirkungen mit anderen Arzneimitteln durchgeführt. Schwangerschaft/Stillzeit: Es gibt
keine kontrollierten klinischen Studien der Anwendung von Opatanol® an schwangeren Frauen. Opatanol® wird bei stillenden Müttern nicht empfohlen. Unerwünschte Wirkungen: Während
der klinischen Prüfungen mit Opatanol® traten keine schwerwiegenden ophthalmologischen oder systemischen Nebenwirkungen
auf. Als häufigste behandlungsbedingte Nebenwirkung wurde okuläre Missempfindung mit einer Häufigkeit von 0.9% angegeben. Okuläre Effekte: Gelegentlich Missempfindung, Pruritus, Hyperämie, Sekret, Keratitis, Lidödem, Trockenes Auge,
Fremdkörpergefühl, Lichtscheu. Systemische Effekte: Häufig Kopfschmerzen, gelegentlich Asthenie, Schwindelgefühl,
Geschmacksstörungen, trockene Nase. Liste: B. Packungen: Tropfflasche aus Kunststoff zu 5 ml. Zulassungsinhaberin: ALCON
SWITZERLAND SA, 6331 Hünenberg. Stand der Informationen: Februar 2009. Weitere Angaben entnehmen Sie bitte dem Arzneimittel-Kompendium der Schweiz 2010.
Referenzen:
1. Abelson MB et al. Combined Analysis of Two Studies Using the Conjunctival Allergen Challenge Model to Evaluate Olopatadine
Hydrochloride, a new Ophthalmic Antialelrgic Agent With Dual Activity. Am J Ophthalmol. 1998;125:797-804
n okul
är
r de
te
Antialler
g
i
ka
en
we
lt
w ei
t2
Nahe am Allergen.
Weit weg von der Allergie.
1
Nr.
nol® ist die
ata
Op
Program overview
Friday, March 18, 2011
Room A
Room B1
Room B3
Room C
(629 persons sem.)
(144 persons sem.)
(120 persons sem.)
(100 persons theat.)
07.30–08.30 Registration
08.30–09.15 Plenary lecture 2 (Room A)
Thomas Schwarz (D)
09.15–10.45 Symposium 7
Basic Immunology
Symposium 8
Clinical Immunology
Symposium 9
Allergology
Doreen Cantrell (UK)
Jean Pieters (CH)
Vigo Heissmeyer (D)
Sergio Abrignani (I)
Cem Gabay (CH)
Hiroshi Takayanagi (J)
Vincenzo Barnaba (I)
Short presentation
Philippe Eigenmann (CH)
Elide Pastorello (I)
Stephan Scheurer (D)
10.45–11.15 Coffee break / Poster viewing / Commercial exhibition
11.15–12.00 Plenary lecture 3 (Joint SGAI and MS Society) (Room A)
David Hafler (USA)
12.15–13.30 Lunch break / Poster viewing / Commercial exhibition
12.15–13.30
Lunch Symposium 2
Lunch Symposium 3
ALK-ABELLO AG and
Basilea Pharmaceutica
International AG
Xanapharm AG and
NutriDis
13.45–14.30 Plenary lecture 4 (Room A)
Jean-Claude Weill (F)
14.30–16.00 Symposium 10
Basic Immunology
Symposium 11
Symposium 12
Clinical Immunology: Novel treatments
Joint SGAI / MS Society
Facundo Batista (UK)
Angela Vincent (UK)
Stuart Tangye (AUS)
Short Presentations
Andrew MacPherson (CH)
Short Presentation
Markus Magerl (D)
François Spertini (CH)
Thomas Kündig (CH)
16.00–16.30 Coffee break / Poster viewing / Commercial exhibition
16.30–17.30 Short Communi-
cations: Basic
Immunology 2
Short Communi-
cations: MS
Researcher Session
Short Communications: Allergy and
Dermatology
17.30–18.000 Awards and Closing Ceremony
21
Lunch Symposium 2
Management of Type-I and Type-IV allergies –
New perspectives and treatment Options
Friday, March 18th 2011, 12:15 - 13:30
Hall B1
Chairmen:
Arthur Helbling & Margitta Worm
12:15 - 12:40 Tablet immunotherapy as a new causal
treatment for children in Switzerland
Peter Eng (Luzern, Aarau CH)
12:40 - 13:05 Anaphylaxis: Jext is next!
Arthur Helbling (Bern, CH)
13:05 - 13:30 Are there different immunological
“finger-prints” of vitamine-A-derivatives?
Margitta Worm (Charité Berlin, DE)
U-272-CH d
Organised by ALK-AbeIló AG and Basilea Pharmaceutica
International AG
Intolerance to
biogenic amines:
an update
Friday March 18 th 2011, 12:15 – 13:30, Room B3
Chairmen: Brunello Wüthrich & Christophe Deluze
12:15 – 12:35
Allergies et intolérances alimentaires
Christophe Deluze (Genève, Switzerland)
12:35 – 13:05 Histamine intolerance: a double blind placebo
controlled provocation study including orally
administered diamine oxidase
Peter Komericki (Graz, Austria)
13:05 – 13:30 Degradation of biogenic amines by diamine
oxidase - an update on substrate specificity,
inhibitors and analytical methods
Albert Missbichler (Vienna, Austria)
Xanapharm AG | Terrassenweg 1a | CH-6301 Zug
www.xanapharm.com | info@xanapharm.com
SGAI_symposium_xana.indd 1
19.01.11 12:22
Program
Friday, March 18, 2011
07.30–08.30 Registration
08.30–09.15 Plenary lecture 2 (Joint SGAI and EADV Society)
Room A
Chair:Nikhil Yawalkar (Berne, CH), Rocco Torricelli (Lugano-Paradiso, CH)
Thomas Schwarz (Kiel, D)
Dermatoimmunology: dogmas going through a radical change
09.15–10.45 Symposium 7: Basic Immunology
Room A
Chair:Silvia Monticelli (Bellinzona, CH), Ed Palmer (Basel, CH)
Doreen Cantrell (Dundee, UK)
Facts, controversies and unresolved issues about serine/threonine
kinases in T lymphocyte biology
Jean Pieters (Basel, CH)
Coronin 1 and the regulation of leukocyte-specific signaling events
Vigo Heissmeyer (Munich, D)
Regulation of microRNA pathway and control of immune functions
Sergio Abrignani (Milano, I)
Human lymphocyte microRNA signatures and their target genes
that regulate T cell differentiation
Symposium 8: Clinical Immunology:
Chronic infections and inflammation
Room B1
Chair:Beat Imhof (Geneva, CH), Mariagrazia Uguccioni (Bellinzona, CH)
Cem Gabay (Geneva, CH)
Mechanisms of articular inflammation and joint damage in arthritis
Hiroshi Takayanagi (Tokyo, J)
Osteoimmunology and the effects of the immune system on bone
Vincenzo Barnaba (Rome, I)
Infections and autoimmunity
Short presentation:
Beatrice Bolinger (Oxford, UK)
CD8 T cell memory inflation after infection with a non-replicating
­adenovirus
24
Symposium 9: Allergology: Food Allergy
(supported by Unilabs)
Room B3
Chair:Arthur Helbling (Berne, CH), Gianluca Vanini (Lugano, CH)
Philippe Eigenmann (Geneva, CH)
IgE-mediated food allergy in children: new diagnostic aspects
Elide Pastorello (Milano, I)
Mediterranean diet: healthy for allergic people?
Stephan Scheurer (Langen, D)
Relevance of immune responses to carbohydrate epitopes and
Maillard reaction products for the pathogenesis of type I allergy
10.45–11.15 Coffee break in Exhibit Hall and poster viewing
11.15–12.00 Plenary lecture 3 (Joint SGAI and MS Society)
Chair:Ludwig Kappos (Basel, CH), Britta Engelhardt (Berne, CH)
David Hafler (New Haven, USA)
Room A
12.15–13.30 Lunch break in Exhibit Hall and poster viewing
12.15–13.30 Lunch Symposium 2
Room B1
Management of type I and type IV allergies – new perspectives and
treatment options
(Organized and sponsored by ALK-ABELLO AG / Basilea Pharmaceutica International AG)
12.15–13.30 Lunch Symposium 3
Intolerance to biogenic amines: an update
(Organized and sponsored by Xanapharm AG and NutriDis)
Room B3
13.45–14.30 Plenary lecture 4 (supported by Humabs Biomed SA)
Room A
Chair:Antonio Lanzavecchia (Bellinzona, CH), Antonius Rolink (Basel, CH)
Jean-Claude Weill (Paris, F)
Multiple layers of B cell memory
25
14.30–16.00 Symposium 10: Basic Immunology
Room A
Chair:Christoph Müller (Berne, CH), Manfred Kopf (Zurich, CH)
Facundo Batista (London, UK)
Early events in B cell activation and initiation of immune response
Stuart Tangye (Darlinghurst, AUS)
Mechanisms underlying defects in humoral immunity in primary
­immunodeficiencies
Andrew MacPherson (Berne, CH)
Commensal intestinal microbes and immune response
Short Presentation:
Fernanda Coelho (Berne, CH)
CXCR5 regulates B cell velocity and microenvironmental distribution,
but not directional movement into B cell follicles
Symposium 11: Clinical Immunology:
Joint SGAI / MS Society
Room B1
Chair:Ludwig Kappos (Basel, CH), Myriam Schluep (Lausanne, CH)
Angela Vincent (Oxford, UK)
Antibody-mediated encephalitides
Short presentations:
Laura Codarri (Zurich, CH)
IL-23 induces GM-CSF secretion by TH17 cells, which is essential
for their pathogenicity in autoimmune disease
Stephanie Hugues (Geneva, CH)
MHC class II-restricted antigen presentation by plasmacytoid dendritic
cells inhibits T cell-mediated autoimmunity
Danielle Burger (Geneva, CH)
Chronic and acute inflammatory conditions determine MEK1
or MEK2 usage as regulators of IL-1 and sIL-1Ra expression:
relevance to MS
L. Hesske (Zurich, CH)
The role of GM-CSF during the effector phase in CNS autoimmune
­inflammation
26
Symposium 12: Novel treatments
(supported by Shire HGT)
Room B3
Chair:Peter Schmid-Grendelmeier (Zurich, CH), Silvy Bach-Bizzozzero
(Bellinzona, CH)
Markus Magerl (Berlin, D)
Hereditary angioedema: pathophysiology and new treatments
François Spertini (Lausanne, CH)
A review of the off-label use of biological in systemic autoimmune
­diseases
Thomas Kündig (Zurich, CH)
The present and the future of allergen specific immunotherapy
16.00–16.30 Coffee break in Exhibit Hall and poster viewing
16.30–17.30 Short Communications: Basic Immunology 2
Room A
Chair: Maries von den Borek (Zurich, CH), Martin Bachmann (Zurich, CH)
BI2-S1
BI2-S2
Notch signaling regulates follicular helper t cell
differentiation
F. Auderset1, M. Charmoy1, S. Schuster1, F. Desgranges1,
U. Koch2, A. Wilson3, S. A. Luther1, H. R. MacDonald3, F. Radtke2,
F. Tacchini-Cottier1
1 Department of Biochemistry, WHO-IRTC, University of Lausanne,
Epalinges
2 Swiss Experimental Cancer Research, Ecole Polytechnique
Fédérale de Lausanne, Lausanne
3 Ludwig Institue for Cancer Research, Lausanne Branch,
University of Lausanne, Epalinges
A new transcription factor that promotes plasma cell
differentiation and cell cycle arrest
S. Chevrier1, D. Emslie1, A. Karnowski1, K. D’Costa1, D. Tarlinton1,
L. M. Corcoran1
1 Walter and Eliza Hall Institute of Medical Research, Melbourne
27
BI2-S3
Unmutated immunoglobulin M efficiently protects
against virus-induced demyelinating disease
L. Cervantes-Barragan1, S. Firner1, C. Perez Shibayama2,
A. Waisman3, I. Bechmann4, V. Thiel1, B. Ludewig1
1 Institute of Immunobiology Kantonsspital St. Gallen, St. Gallen
2 UIMIQ, Centro Medico Nacional, IMSS, Mexico City
3 University of Mainz, Mainz
4 Institut für Anatomie, Universität Leipzig, Leipzig
BI2-S4
Antibody-Mediated Control of Helminth-Induced Basophilia
T. Herbst1, M. Prati2, M. Kulagin2, R. Stettler2, P. Merky2,
S. F. Verbeek3, M. Camberis4, G. Le Gros4, N. Harris5
1 Microbiology, ETH Zurich, Zurich
2 Intestinal Immunology, SV, GHI EPFL, Lausanne
3 Leiden University Medical Center, Leiden, Netherlands
4 Malaghan Institute of Medical Reseach, Wellington, New Zealand
5 Swiss Vaccine Research, Global Health Institute, Lausanne
BI2-S5
NF-kB p50 regulates mast cell survival in part through
upregulation of miR-146a
N. Rusca1, L. Deho1, P. Larghi2, A. Sica2, S. Monticelli1
1 Institute for Research in Biomedicine, Bellinzona
2 Istituto Clinico Humanitas, Rozzano (MI)
28
Short Communications: MS Researcher Session
Room B1
Chair: Ludwig Kappos (Basel, CH), Myriam Schluep (Lausanne, CH)
MS-S1
MS-S2
MS-S3
Central Role of JC Virus-Specific Bifunctional
CD4+ Th1-2 Lympho­cytes in PML-Immune Reconstitution
Inflammatory Syndrome
I. Jelcic1, L. Aly2, S. Yousef2, S. Schippling2, S. Bofill-Mas3,
R. Girones3, T. Weber4, M. Linnebank1, M. Sospedra2, R. Martin2
1 Department of Neurology, University Hospital Zurich, Zurich,
Switzerland
2 Institute for Neuroimmunology and Clinical MS Research (inims),
Center for Molecular Neurobiology (ZMNH), University Medical
Center Hamburg-Eppendorf, Hamburg, Germany
3 Department of Microbiology, Faculty of Biology, University of
Barcelona, Barcelona, Spain
4 Department of Neurology, Marienkrankenhaus, Hamburg,
Germany
EEG background activity is correlated to a measure of
cognitive speed in MS
M. Hardmeier1, I. K. Penner2, Y. Naegelin1, R. Zimmermann1,
F. Hatz1, L. Kappos1, Chr. Schindler3, St. Rueegg1, P. Fuhr1
1 Department of Neurology, University Hospital Basel, Basel
2 Department of Cognitive Psychology and Methodology,
University of Basel, Basel
3 Institute of Social and Preventive Medicine, University of Basel,
Basel
TET-induced expression of claudin-1 in brain endothelium
reduces edema formation and clinical disease in an animal
model of multiple sclerosis
B. Engelhardt1, F. Pfeiffer1, J. Schäfer1, S. Tauber1, U. Deutsch1
1 Theodor Kocher Institute, University of Berne, Berne
29
MS-S4
Control of gait in multiple sclerosis: the interference
between locomotion and cognitive functions
G. Allali1, M. Laidet1, F. Assal1, M. Chofflon1, S. Armand2,
P. H. Lalive1
1 Department of Clinical Neurosciences, Division of Neurology,
Geneva University Hospital and University of Geneva, Geneva
2 Willy Taillard Laboratory of Kinesiology, Geneva University
Hospital and University of Geneva, Geneva
Short Communications: Allergy and Dermatology
Chair: M. Bauer (Olten,CH), Th. Kündig (Zurich, CH)
Room B3
AD-S1
Patterns of sensitizations to single allergens analyzed
by Microarray: Seroprevalence and variations in cohorts of
formerly schoolchildren from 1986 and 2006
M. Gassner1, P. Schmid-Grendelmeier2
1 Allergologische Praxis, Grabs
2 Institute of Dermatology, University Hospital of Zurich, Zurich
AD-S2
Immunotherapy with Bet v 1 derived contiguous
overlapping peptides leads to long term immunoregulatory
responses
F. Spertini1, N. Barbier1, A. C. Thierry1, R. Audran1, V. Charlon2,
C. Reymond2
1 Division of Immunology and Allergy, CHUV, Lausanne, Switzerland
2 Anergis SA, Epalinges, Switzerland
AD-S3
Clinical effective apple desensitization in birch allergic
patients with oral allergy syndrome
B. Schnyder1, R. Gerber1, M. Rudin1, P. Kopac2, T. Gentinetta3,
Ch. Pichler1, O. Hausmann1, W. J. Pichler1
1 Clinic for Rheumatology and Clinical Immunology/Allergology,
Inselspital, Berne
2 University Clinic of Respiratory and Allergic Diseases, Golnik,
Slovenia
3 ADR-AC GmbH, Holligenstrasse 91, Berne
30
AD-S4
IgE-mediated allergy to recombinant human growth
hormone (somatotropin)
I. Heijnen1, K. Scherer-Hofmeier2, S. Link1, A. Bircher2
1 Medical Immunology, Laboratory Medicine, University Hospital
Basel, Basel
2 Allergy Unit, Dermatology, University Hospital Basel, Basel
AD-S5
Allergy to betalactam antibiotics in children:
results of a 20-year study
Y. Perrin, pediatric allergy and immunology, CHUV, Lausanne
C. Ponvert1, M. Le Bourgeois1, C. Karila1, C. Delacourt1,
P. Scheinmann1, J. de Blic1
1 Paris Descartes University, Department Paediatrics, Pulmonology,
Allergy and Dermatology Service, Sick Children’s Hospital, Paris
AD-S6
Acute localized exanthematous pustulosis (ALEP)
caused by finasteride
L. Feldmeyer1, S. Tresch1, A. Cozzio1, J.Kamarashev1, Th. Harr1,
P. Schmid-Grendelmeier1, L.E. French1
1 Institute of Dermatology, University Hospital of Zurich, Zurich
17.30–18.00 Awards and Closing Ceremony
31
Chairpersons and speakers
Werner Aberer, Graz (A)
Sergio Abrignani, Milano (I)
Hans Acha-Orbea, Lausanne (CH) Martin Bachmann, Zurich (CH)
Facundo Batista, London (UK)
Silvy Bach-Bizzozzero, Bellinzona (CH)
Vincenzo Barnaba, Rome (I)
Madeleine Bauer, Olten (CH)
Andreas Bircher, Basel (CH)
Onur Boyman, Zurich (CH)
Doreen Cantrell, Dundee (UK)
Bernard Clot, Payerne (CH)
Marco Colonna, St. Louis (USA)
Eric Dayer, Sion (CH)
Gennaro De Libero, Basel (CH)
Philippe Eigenmann, Geneva (CH) Britta Engelhardt, Berne (CH)
Walter Fierz, Schaan (CH)
Massimiliano Fontana, Mendrisio (CH)
Lars French, Zurich (CH)
Cem Gabay, Geneva (CH)
Fabienne Gay-Crosier, Carouge (CH)
Alberto Giannetti, Modena (I)
Stefano Gilardi, Locarno (CH)
Fabio Grassi, Bellinzona (CH)
David Hafler, New Haven (USA)
Nicola Harris, Lausanne (CH)
Arthur Helbling, Berne (CH)
Vigo Heissmeyer, Munich (D)
Ingmar Heijnen, Basel (CH)
Georg A. Holländer, Basel (CH)
Beat Imhof, Geneva (CH)
Ludwig Kappos, Basel (CH)
Franco Keller, Bellinzona (CH)
Manfred Kopf, Zurich (CH)
Thomas Kündig, Zurich (CH)
Olivier Lantz, Paris (F)
32
werner.aberer@medunigraz.at
abrignani@ingm.org
Hans.Acha-Orbea@unil.ch
martin.bachmann@cytos.com
facundo.batista@cancer.org.uk
Silvy.Bach-Bizzozero@eoc.ch
vincenzo.barnaba@uniromal.it
m.bauer@hin.ch
andreas.bircher@uhbs.ch
Onur.Boyman@usz.ch
d.a.hill@dundee.ac.uk
Bernard.clot@meteoswiss.ch
mcolonna@pathology.wustl.ed
eric.dayer@consilia-sa.ch
gennaro.delibero@unibas.ch
philippe.eigenmann@hcuge.ch
britta.engelhardt@tki.unibe.ch
fierz@risch.ch
Massimiliano.Fontana@eoc.ch
lars.french@usz.ch
Cem.Gabay@hcuge.ch
fgaycrosier@safemail.ch
alberto.giannetti@unimore.it
gilardi@dermastudio.ch
fabio.grassi@irb.unisi.ch
david.hafler@yale.edu
nicola.harris@epfl.ch
Arthur.Helbling@spitalnetzBerne.ch
vigo.heissmeyer@
helmholtz-muenchen.de
heijnenI@uhbs.ch
georg-a.hollaender@unibas.ch
beat.imhof@unige.ch
lkappos@uhbs.ch
franco.keller@eoc.ch
manfred.kopf@env.ethz.ch
thomas.kuendig@usz.ch
olivier.lantz@curie.net
Antonio Lanzavecchia, Bellinzona (CH)
Alison Levoguer, Birmingham (UK)
Burkhard Ludewig, St. Gallen (CH)
Andrew MacPherson, Berne (CH)
Markus Magerl, Berlin (D)
Silvia Monticelli, Bellinzona (CH)
Christoph Müller, Berne (CH)
Christian Münz, Zurich (CH)
Claudio Ortolani, Milano (I)
John O’Shea, Bethesda (USA)
Annette Oxenius, Zurich (CH)
Ed Palmer, Basel (CH)
Elide Pastorello, Milano (I)
Jean Pieters, Basel (CH)
Stephan Regenass, Zurich (CH)
Antonius G. Rolink, Basel (CH)
Federica Sallusto, Bellinzona (CH)
Stephan Scheurer, Langen (D)
Myriam Schluep, Lausanne (CH)
Peter Schmid-Grendelmeier, Zurich (CH)
Thomas Schwarz, Kiel (D)
Daniel Speiser, Lausanne (CH)
François Spertini, Lausanne (CH)
Steven Stapel, Amsterdam (NL)
Hiroshi Takayanagi, Tokyo (J)
Stuart Tangye, Darlinghurst (AUS)
Margot Thome-Miazza, Lausanne (CH)
Rocco Torricelli, Lugano-Paradiso (CH)
Mariagrazia Uguccioni, Bellinzona (CH)
Maries van den Broek, Zurich (CH)
Gianluca Vanini, Lugano (CH)
Angela Vincent, London (UK)
Jean-Claude Weill, Paris (F)
Brunello Wüthrich, Zollikerberg (CH)
Nikhil Yawalkar, Berne (CH)
lanzavecchia@irb.unisi.ch
alison.levoguer@bindingsite.co.uk
burkhard.ludewig@kssg.ch
andrew.macpherson@insel.ch
markus.magerl@charite.de
silvia.monticelli@irb.unisi.ch
christoph.mueller@
pathology.unibe.ch
Christian.Muenz@usz.ch
c.ortolani@allergologico.it
osheaj@arb.niams.nih.gov
oxenius@micro.biol.ethz.ch
ed.palmer@unibas.ch
elide.pastorello@
ospedaleniguarda.it
jean.pieters@unibas.ch
stephan.regenass@usz.ch
Antonius.Rolink@unibas.ch
federica.sallusto@irb.unisi.ch
schst@pei.de
myriam.schluep@chuv.ch
peter.schmid@usz.ch
tschwarz@dermatology.uni-kiel.de
daniel.speiser@hospvd.ch
Francois.spertini@chuv.ch
sstapel@xs4all.nl
taka.csi@tmd.ac.jp
s.tangye@garvan.org.au
margot.thomemiazza@unil.ch
rtorricelli@bluewin.ch
mariagrazia.uguccioni@irb.unisi.ch
maries@van-den-broek.ch
gianluca.vanini@bluewin.ch
angela.vincent@imm.ox.ac.u
jean-claude.weill@inserm.fr
bs.wuethrich@bluewin.ch
nikhil.yawalkar@insel.ch
33
General Information
Date
March, 17–18, 2011
Congress Venue
Palazzo dei congressi, Piazza Indipendenza 4, CH-6900 Lugano
Presidents of the Organizing Committee
Federica Sallusto, IRB, Bellinzona (E-mail: federica.sallusto@irb.unisi.ch)
Brunello Wüthrich, STAI, Zollikerberg (E-mail: bs.wuethrich@bluewin.ch)
Congress Language
English (no simultaneous translation)
Credits for two days (March 17–18, 2011)
Swiss Society for Allergology and Immunoloy
Swiss Society of Dermatology and Venereology
Swiss Society of Hematology
Swiss Society of Infectious Diseases Swiss Society of Neurology
Swiss Federal Veterinary Office
5 credits (17.3.) / 6 credits (18.3.)
5 credits (17.3.) / 8 credits (18.3.)
5 credits
recognized by other societies
3 credits
1 day
Registration fees
Members SSAI, SSDV, MS Society (2 days)
Members SSAI, SSDV, MS Society (1 day)
Non-Members (2 days)
Non-Members (1 day)
Assistant Doctors/Students (2 days)
Assistant Doctors/Students (1 day)
Gala dinner
34
CHF 250.–
CHF 150.–
CHF 310.–
CHF 160.–
CHF 180.–
CHF 90.–
CHF 100.–
Method of payment
Payments should be made by
Banktransfer to (free of charge)
Bank:
UBS AG, CH-6002 Lucerne (BC 248)
Beneficiary: Convention Team Lucerne AG
Account:
0248-469471.06T
Remark:
SGAI 2011
IBAN:
CH830024824846947106T
BIC:
UBSWCHZH80A
Credit cards (VISA, MasterCard)
Cancellation
Cancellations until February 1, 2011: Refund of total amount paid minus
CHF 50.– per person for administrative charges. No refund after this date.
Cancellations must be written to the Congress Organization.
Posters
Posters will be exhibited in the poster area from Thursday to Friday
(size of posters: 125 cm × 200 cm (width × height).
Industry exhibition
The exhibition is located in the main congress area at the Convention Center
and will be open from Thursday, 10.00 to Friday, 18.00.
Access by train or by car
The Lugano railroad station offers fast and easy connections to most Swiss
and European destinations. For information and time table www.sbb.ch.
From the railroad station the Convention Centre can be reached by bus (No. 2,
direction «Cornaredo» stop at «Palazzo dei congressi») or by taxi.
Lugano is served by the motorway axis that directly connects northern Europe
to the Mediterranean. For more information www.lugano-tourism.ch.
Parking spaces are available at the Convention Centre. Daily parking tickets
at a reduced rate can be purchased at the Registration desk.
35
Access by plane
Lugano-Agno airport is connected with non stop flights to Zurich and Geneva
as well as to Rome. Darwin Airline (www.darwinairline.ch/reservation center
Tel. 0848 177 177) offers to SGAI delegates a special flight rate of CHF 300.–
ALL INCLUSIVE for the round trip Geneva–Lugano–Geneva. From the
­airport the city center can be reached by shuttle bus (www.shuttle-bus.com)
or by taxi.
Milan Malpensa is the closest (60 km) major international airport with regular
shuttle bus service to Lugano (www.malpensaexpress.ch).
Prizes
SGAI-Prize (sponsored by CSL Behring)
The poster prize award in the amount of CHF 1000.– will be given to the first
author of the best poster in the category «Basic Immunology», «Clinical Immunology» and «Allergology» incl. «Allergy Laboratory Diagnostic».
Brunello Wüthrich Allergy Poster Prize (CHF 1000.–) will be awarded to
an original and interesting allergy case description or casuistics.
The annual award of CHF 10 000.– of the Allergy Foundation UlrichMüller-Gierok will be given for an excellent peer reviewed Swiss publication
in clinical Allergology.
36
Flow2 CAST®
Leave nothing to chance
Routinefriendly
cellular allergy diagnostics for
immediate-type reactions
The most often presumed etiology of life-threatening anaphylactic reactions are caused by food (33%), insect venoms (14%)
and drugs (13%). In these specific fields of allergy the BÜHLMANN
CAST® are at the forefront of the cellular allergy in vitro diagnosis.
This basophil activation test offers an easy, fast (1h), reliable, flowcytometric and whole blood based solution. This routinefriedly test
identifies the culprit allergen clearly thanks to superior specificity and
sensitivity. It supports the diagnosis where specific IgE is not sufficient.
Since many years BÜHLMANN Laboratories AG, Schönenbuch, is
the only company worldwide that provides cellular allergy tests
in combination with standardised allergens (>150). We use this
knowledge for the development of new tests, like the unique activation measurement via CD63 and CD203c – CE marked soon.
BÜHLMANN Laboratories AG
www.buhlmannlabs.ch
Sponsors
The Scientific and Organizing committee wish to acknowledge the financial
support of the following companies and institutions:
Lunch Symposia:
ALK-Abello AG
Basilea Pharmaceutica International Ltd
Merck Serono SA
NutriDis Xanapharm AG
Symposia:
Humabs-Biomed SA
SGA (Schweiz. Gesellschaft für Aerobiologie)
SHIRE HGT
Sodiag SA
Unilabs
Gold Sponsor:
Novartis Pharma Schweiz AG
Silver Sponsor:
CSL Behring
Bronze Sponsor:
Pevion Biotech AG
Sponsors:
Abbott AG
Bühlmann Laboratories AG
Città di Lugano
CSL Behring
Dustri Verlag
IBSA
Life Technologies
Phadia AG
RUWAG Diagnostics
Schweiz. Multiple Sklerose Gesellschaft
Siemens Health Care Diagnostics AG
Teva Pharma AG
Zeller Medical
38
Exhibitors
AbD Serotec
AID GmbH
Alcina AG
ALK-ABELLO AG
Allergopharma AG
Allergy Care AG
Basilea Pharmaceutica International
Becton Dickinson
BioConcept
Biotek Instruments GmbH/Witec AG
Biotest (Schweiz) AG
CSL Behring
Dustri Verlag
Enzo Life Sciences AG
EUROIMMUN Schweiz AG
LuBioScience GmbH
MABTECH AB
Merck Millipore
Merck Sharp & Dohme AG
Miltenyi Biotec GmbH
Novartis Pharma Schweiz AG
Nutricia
PerkinElmer
Phadia AG
Roche Pharma (Schweiz) AG
RUWAG Diagnostics
Schülke & Mayr AG
Schweiz. Verband für Aerobiologie
Schweiz. Verband dipl. Ernährungsberater/innen HF/FH
Shire Human Genetic Therapies
Siemens Healthcare Diagnostics AG
Sodiag SA
STEMCELL Technologies
Teomed AG
Thermo Scientific
Trimedal AG
ViroPharma SPRL
Xanapharma AG
Zeller Medical
Düsseldorf (D)
Strassberg (D)
Aesch
Volketswil
Therwil
Adliswil
Basel
Allschwil
Allschwil
Lucerne
Rupperswil
Berne
Munich (D)
Lausen
Lucerne
Lucerne
Nacka (S)
Guyancourt (F)
Opfikon-Glattbrugg
Bergisch Gladbach (D)
Berne
Domdidier
Beaconsfield (UK)
Steinhausen
Reinach
Bettlach
Zurich
Berne
Berne
Montreux
Zurich
Losone
Grenoble (F)
Greifensee
Lausanne
Brüttisellen
Brussels (B)
Zug
Romanshorn
39
Map of Lugano
P +R
CE
RE
SI
O
LI
EL
LVAT
ORE
→
IA
CC
CA
AN
UIS
SIA
VIA
CARO
NA
VIA
Monte S. Salvatore
PAZZALLO
40
5
O
DIS
RA
PA
VIA
RZI
A
RIV
F. ZO
GUID
INO
BO
SC
VIA
CIA
NI
PO
LE
LL
CO
VIA
→
VIA
G. VI
PICO
DIA
P
VIA
TE
ON
PE
DE
M
SA
CHIE
ALLA
VIA
UOLE
ZZO
CARI
LIO
IN
NA
ERLI
DDEI
VIA TA
VIAM
LI ORTI
LIDO
GGI
TIG
14
Monte Brè
P
P
7
LUGANO
VIA DELLE SCUO
→
→
VIA AG
VIA AL
IO
1
VIA
NA
A
VIA
Lido
P
LINA
GG
COR
LA
WiFi Lugano
MO
MA
CON
CAST
AGNO
P
12
VIA CERESIO
→
E
O
GIA
CO
M
VIA
CA
RO
NA
M
.D
A
VIA
LI
P
VIALE
A
LLI
→
VIA
INO
ZAL
PAZ
VIA
O CATT
ANEO
Parco Civico
RTO
VIA
VIA CAMPO MARZIO
CARL
→
P
A →
→
→
VIALE
NIC
E SC
ANO
DELL
L. C
DEI FA
VIA
VIA
P
P
VIGANELLO
P
VIALE
→
→
VIA
SANT
A
→ VIA AL CHIOSO
VIA PIETRO CAPEL
→
A
ARATE
BALE
VIALE CASS
O
CASSARATE
P
P
P
1
Grand Hotel Villa Castagnola au Lac
2
Grand Hotel Eden
3
Hotel Splendide Royal
4
De la Paix
5
Hotel Du Lac
6
Holiday Inn Lugano Centre
7
Lido Seegarten
8
Deltino
9
Colorado
10
Hotel Dischma
11
Federale
12
Walter au Lac
13
Zurigo – Garni
14
Atlantico – Garni
15
Besso – Garni
16
Pestalozzi
17
San Carlo – Garni
S
P
CASTAGNOLA
E.
UOLE
→
HI
NG
RT
E
BE
LA
FIN
2
→
BO
LE SC
ETTA
→
DEL
GER
FIL
IP
EB
PP
→
RS
CO
→
→
EL
VE
ZIA
H
P
PARADISO
V.
G
→
S. SA
V.LE
6
VIA LA
M
P
STR
ELV
SO
A
I
VIA
EZIA
→
DA
PIO
VIA
→
ALBE
O
O
ER
N
AD
M
C.
VIA
RIO
O
ET
→
→
TI
UT
O
AG
TR
EV
AN
SE
VIA
GIU
→
→
I
IN
SC
AN
O
→
AN
EF
ST
LE
VIA
E
AL
VIA
I
PER
VIA G. LUVINI VIA
FR
I
→ VIA F
.P
EL
L
ON
→
PR
VIA
OLI
VIA
A
VIA
V
STINO
SOLDAT IA
I SA
SS
AG
O
O
RS
GE
VIA
→
CA
VIA
GALL
I
NT
VIA REGAZZONI
FFS
STAZIO
NE
BOSS
SA
16
ZI
TT
A
FF
SS
LL
A
VIA S
.C
TA
→
P
EL
V.
V
M
E
PP
SE
IU
G
A.
RIV
A
VI
A
O
N
I
→
IN
ET
RIVA
RA
→
Casinò Lugano
→
ER
OZ
AZ
Z
VIA A.
IN
I
RIVA
→
SS
PE
ST
AL
BR
P
BU
SALITA VIARNO
È→
ON
G.
I
VIA
CA
O
TE
NE
VIA
RR
VIA DEL SOLE
CE
3
→
→ VIA
→
13
→
VIA
SE
A Palazzo dei Congressi
→
RIN
LP
CA
VIA
VIA
P
A
RIV
→
CATTORI
PE
SEP
GIU
10
VIA
P
→
FE
P
LA
VIA
VIA FONTANA
4
VIA
←
P
ON
AD
PRE
FO
VIA RIVIERA
MO
ENTRATA
ENTREE
EINGANG
LUGANO SUD
VIA
→ VIA
BASILEA
ARI
VIA ROD
VIA TA
P
A
LB
8
VIA
TA
R
OT
NG
SA
VIA
O
M
M
RE
CO
I
IN
RR
OM
BO
VIA
SSINO
O
P
9
VIA
ADIS
NO
P
→
VIA DELLA POSTA
→
VIA
INO
SOLD
VIA
GO
VIA SOREN
E SC
DELL
P
E
NT
ME
LORETO
O
LIT
A
LO
VIA
UOLE
TO
ET
GH
LA
AL
VIA
VIA
M
P
CLE
A
OTT
AIN
G. M
VIA
AR
GENTILINO
RS
→
→
17
I
P
PAR
A
→
A
LUGANO AGNO
PONTE TRESA
VIA
→
VIA
T
ON
VR
P
CO
→
P
E
A
NT
11
P
ES
TR
P
→
SORENGO
VIA
P
P
INE
COR
I
TT
FO
LE
B.
LE
MO
EM
VIA
G
B.
V.
AV
DO
AR
A
CA
M
VIA
LE
ON
I
VIA SORENGO
V. G
P
→
CO
MO
P
P
→
RT
IVA
L
15
M
VIA
P
→
VIA
CCO
U
NC
NI
M
→
P
→
DO
TAR
GOT
→
→
P
SAN
→
NO
MA
VIA
VIA
A
AIE
GIO
VA
N
→
VIA
→
E
→
GA
→
NO
SAG
S
P
VIA
P
P
O
NI
→
LU
→
RIG
→
CO
VIA
ZU
→
A
IV
RT
VIA
VIA AL PONTE
→
O
LL
→ VIA
P
O VIA
RIG
→
C
LU
VIA
ZU
VIA
TA
IA
IN
LL
→
EN
BO
GL
→
DE
→
NA
VIA BESSO
VIA
ANZO
VIA
→
→
REG
TE
ERE
S
TES
→
VIA
DELLA SALUTE
→
NA
DO
TE
AM
→
P
ON
SE
BR
ON
LT
R
VIA
→
AD
→
M
VIA LEMA
INO
LVA
SE
VIA
→
V. B
NO
O
→
O
CIN
LU
O
VIA
OLI
BON
RD
STAUSIO
SS
P
DEI
TT
A
MASSAGNO
VIA
G.
M
BE
→
→
BE
VIA
VIA
SE
S
TE
O
P
VIA
LAR
G
→
OR PO
N
E
T
RE
P
→
CINQUE VIE
DOTT
SA
VIA CA
VIA
VIA
A
LE
VIA
VIA
→
P
VI
HIN
A
VIA
H
VI
A
IC
RR
TO
VIA
BREGANZONA
RI
PO
SKATE PARK
TE
VIA
GGIO
VIA
→
ER
SS
MARAINI
→
VIA BIO
E
ET
ENTRATA
IO
ENTREE
EMIL
VIA
EINGANG
LUGANO NORD
V
tzt
X® je er
A
Z
A
nd
GR
ür Ki 2 0 1 1
f
h
c
.
au
b 1.3
NEU
K a ss
enz
sig
uläs
ke i t
a
ACHSE
RW
N
U-269-CH d
R
LASS
EN
EN
DE
KIN
ZUGE
E&
E
Die erste
Immuntherapie in
Tablettenform bei
Gräser-Allergie
AB 5 JAHR
GRAZAX®:
Zusammensetzung: Lyophilisierte Allergentablette aus Gräserpollen von Phleum pratense zur spezifischen Immuntherapie. Eine Tablette enthält 75 000 SQ-T. Hilfsstoffe: Gelatine, Mannitol. Indikation: Behandlung von Gräserpollen-bedingter Rhinitis und Konjunktivitis bei Kindern (5 Jahre und älter) und bei erwachsenen Patienten mit positivem Prick-Test und/oder positivem spezifischem IgE-Test
auf Phleum pratense. Bei Kindern muss die Indikation sorgfältig gestellt werden. Dosierung: Erwachsene, Kinder (5 Jahre und älter)
und ältere Patienten: 75 000 SQ-T (1 Dosis) einmal täglich, unter die Zunge. Kontraindikationen: Überempfindlichkeit gegen einen der
Hilfsstoffe. Systemische Erkrankungen, die das Immunsystem beeinträchtigen wie z.B. Immunkomplexkrankheiten und Immundefektkrankheiten. Patienten mit unzureichend behandeltem oder schwerem Asthma (bei Erwachsenen FEV1<70%, bei Kindern FEV1<80%
des Vorhersagewertes nach adäquater pharmakologischer Therapie). Vorsichtsmassnahmen: Entzündliche Zustände in der Mundhöhle mit schwerwiegenden Symptomen. Nach operativen Eingriffen in der Mundhöhle, Zahnextraktionen, Ausfall eines Milchzahnes bei
Kindern die Behandlung mit Grazax für 7 Tage unterbrechen. Kinder, die gleichzeitig Asthma und eine akute Infektion der oberen Atemwege haben, Behandlung bis zum Abklingen der Infektion unterbrechen. Bei Patienten, die bereits früher eine systemische Reaktion auf
eine subkutane Immuntherapie mit Gräserpollen hatten, kann das Risiko erhöht sein, eine ernsthafte Reaktion auf Grazax zu entwickeln.
Kinder unter 12 Jahren müssen nach Einnahme der Tabletten mind. 30 min unter Aufsicht einer erwachsenen Person bleiben. Interaktionen:
gleichzeitige Behandlung mit symptomatisch wirkenden Antiallergika kann die Toleranzgrenze des Patienten für die Immuntherapie erhöhen.
Schwangerschaft/ Stillzeit: Keine Behandlung mit Grazax während der Schwangerschaft einleiten. Unerwünschte Wirkungen: Gastrointestinal: Juckreiz im Mund, Mundschwellung, oropharyngeale Schwellung, Dyspepsie, Übelkeit, Zungenschwellung, -brennen, die selten
zu Atembehinderung führen können. Atmungsorgane: Halsirritationen, Niesen, Husten, Asthma, Pharyngitis, Rhinorrhoe, Rhinits, Engegefühl
im Hals. Augen: Juckreiz am Auge, Konjunktivitis. Ohr: Juckreiz im Ohr. NS: Kopfschmerzen, orale Parästhesie. Haut: Juckreiz. Patienten sollen angewiesen werden, sofort einen Arzt zu konsultieren, falls schwerwiegende system. Reaktionen, Angioödem, Schluckschwierigkeiten,
Atemschwierigkeiten, Stimmverränderungen, Hypotonie oder Klossgefühl im Hals auftreten. In solchen Fällen soll die Behandlung abgebrochen werden, entweder für immer oder bis auf andere Anweisung des Arztes. Packungen: 30, 100 Tabletten. Abgabekaterorie: A . Stand August 2010. ALK-Abelló, Industriestrasse 30, 8604 Volketswil, Tel. 044 908 21 00. www.alkabello.com. Weitere Informationen entnehmen sie bitte dem aktuellen Arzneimittelkompendium der Schweiz.
ABBOTT AG
Abbott International
Neuhofstrasse 23
Postfach
CH-6341 Baar
ABBOTT AG
Abbott International
Tel. 041 768 43 33
Fax 041 768 43 53
Neuhofstrasse 23
Postfach
CH-6341 Baar
Tel. 041 768 43 33
Fax 041 768 43 53
Abbott Rheumatology Grant 2011
Abbott Rheumatology Grant 2011
Abbott, your Partner for Scientific Research in Rheumatology and Immunology,
announces with great pleasure the “Abbott Rheumatology Grant” 2011.
This grant is intended to support clinically oriented research in rheumatology and clinical
immunology.
Criteria for applicants
The applicants are physicians meeting the following criteria:
Abbott,
your Partner for Scientific Research in Rheumatology
•
Age: 45 years or less.
and
Immunology,
announces with great pleasure the “Abbott
•
Location: The principal investigator and his/her study center have to be located in Switzerland.
Rheumatology
Grant”
2011. and/or other centers (inside or outside of Switzerland) is
A collaboration with
other investigators
allowed and has to be specified in the application.
•
Responsibilities:
The principal
is responsible
for theoriented
project and allresearch
legal
This
grant
is intended
toinvestigator
support
clinically
in
permissions (ethic committee, Swissmedic notification, insurance, etc.).
rheumatology and clinical immunology.
•
•
Follow-up: The applicant has to present the research project, as well as the final data, at the
scientific session of the following SGR/SSR. The applicant will provide an annual report about
the development to the President of the Jury Board until finalisation of the research project.
Written consent: (Date and Signature) from the applicant and the Head of the Department or
Institution where the project is planned to be conducted.
Prize sum: 50'000 Swiss Francs
Criteria for the study
• Jury
Research
fields: Clinically oriented research in rheumatology and/or in the field of clinical
The
Board:
immunology. In both cases, the planned study must have relevance to patients.
President:
Prof.
Beat
Michel,
•
Legal form: Investigator
driven
study
accordingZurich
to GCP and/or GLP.
• President:
Type of trial : Prospective
retrospective. So, Lausanne
Vice
Prof.orAlexander
•
Status of the project: Planned or ongoing.
Members:
Prof. André Aeschlimann, Zurzach
Award’s description
Prof.
Cem Gabay, Geneva
The Abbott Rheumatology Grant supports one study per year.
•
Award: The winner will
receive
50’000.CHF (excl.VAT).
Prof.
Paul
Hasler,
Aarau This award will be remitted to the
institution account, after announcement of the selected project.
Prof. Johannes von Kempis, St. Gallen
•
Announcement: The president of the Jury will announce the name of the winner at the
SGR/SSR Congress Prof.
2011 inAlan
Berne.Tyndall, Basel
•
Project selection: According to the criteria defined by the Abbott Rheumatology Grant Jury
Prof. Peter Villiger, Bern
Board.
•
The Jury Board:
President:
Prof. Beat Michel, Zurich
st
Deadline:Members:
Participants have
to submit their applications by 1 June 2011
Prof. André Aeschlimann, Zurzach
Application Form and more
information:
Prof. Cem
Gabay, Geneva www.abbott-grants.ch
Prof.via
PaulE-Mail:
Hasler, Aarau
Contact: Dr. Patrick Dufner
patrick.dufner@abbott.com or via
Prof. Johannes von Kempis, St. Gallen
Tel. 041 768 43 33
Prof. Alexander So, Lausanne
Announcement of the winner
the SGR/SSR
Congress in Berne,
Prof. Alanat
Tyndall,
Basel
7th – 9th September 2011 Prof. Peter Villiger, Bern
Timelines
•
•
Deadline: Participants have to complete the template available on www.rheuma-net.ch,
www.rheuma-schweiz.ch, www.sgai-ssai.ch or www.abbott-grants.ch and submit their application
and/or questions to Dr. Patrick Dufner (Abbott AG) by 1st June 2011 via E-Mail:
patrick.dufner@abbott.com – via Tel. 041 768 43 33
th
th
Announcement of the winner at the SGR/SSR Congress in Berne, 7 – 9 September 2011
MED_RAGrant_Billboard_2011_V1